Letter to Gilead Sciences requesting expansion of not-for-profit price of key drug L-AMB to include indication of cryptococcal meningitis

16 February 2017
Open letter to request Gilead Sciences to expand its not-for-profit price of L-AMB to include the indication of cryptococcal meningitis for all low- and middle-income countries, where the disease burden is greatest, such that people with HIV may access the best possible treatment with fewer side effects, regardless of where they live.

Page updated: 16 February 2017
↑ To top